Chinook Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Chinook Therapeutics

08/08/2022 23:00

* Chinook Therapeutics Inc  KDNY.OQ  reported a quarterly
adjusted
loss of 61 cents​​ per share for the quarter ended in June. The
mean expectation of six analysts for the quarter was for a loss
of 61 cents per share.
    * Revenue rose 1,129.4% to $418.00 thousand from a year ago;
analysts expected $416.67 thousand. 
    * Chinook Therapeutics Inc's reported EPS for the quarter
was a
loss of 61 cents​.
    * The mean earnings estimate of analysts had risen by
about 14.8%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Chinook Therapeutics Inc shares had risen by 16.9% this
quarter and gained 25.3% so far this year.
    * The company reported a quarterly loss of $37.65 million.
    * Wall Street's median 12-month price target for Chinook
Therapeutics Inc is $31.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 9 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 8
at 10:00 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.61          -0.61          Met
 Mar. 31 2022      -0.67          -0.54          Beat
 Dec. 31 2021      -0.68          0.14           Beat
 Sep. 30 2021      -0.84          -0.69          Beat